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Summary The results of preclinical and clinical studies indicate enhanced antineoplastic activity of topotecan
(SKF 104864-A) when administered as a chronic treatment. We determined the apparent bioavailability and
pharmacokinetics of topotecan administered orally to 12 patients with solid tumours in a two-part crossover
study. The oral dose of 1.5 mg m 2 was administered as a drinking solution of 200 ml on day 1. The i.v. dose
of 1.5 mg m-2 was administered as a 30 min continuous infusion on day 2. The bioavailability was calculated
as the ratio of the oral to i.v. area under the curve (AUC) calculated up to the last measured time point. The
oral drinking solution was well tolerated. The bioavailability revealed moderate inter-patient variation and was
30%+7.7% (range 21-45%). The time to maximum plasma concentration after oral administration (Tmax)
was 0.78 h (median; range 0.33-2.5). Total i.v. plasma clearance of topotecan was 824+ 154 ml min-' (range
535-1068 ml min-'). The AUC ratio of topotecan and the lactone ring-opened hydrolysis product (hydroxy
acid) was of the same order after oral (0.34-1.13) and i.v. (0.47-0.98) administration. The bioavailability of
topotecan after oral administration illustrates significant systemic exposure to the drug which may enable
chronic oral treatment.
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Topotecan (SKF 104864) [(S)-9-dimethylaminomethyl-10-
hydroxycamptothecin hydrochloride] is a semisynthetic
water-soluble analogue of camptothecin (Hsiang and Liu,
1988). Like camptothecin, topotecan is a specific inhibitor of
topoisomerase I (Hsiang and Liu, 1988). Topotecan
incorporates a stable basic side-chain at the 9-position of
the A-ring, which provides water solubility at acid pH.
Topotecan is converted to its lactone ring-opened hydrolysis
product (hydroxy acid), which reversible pathway is strongly
pH dependent. The biological activity of the hydroxy acid
has not been fully elucidated (Kingsbury et al., 1991). Anti-
tumour activity has been demonstrated in preclinical models
and in phase I and II studies (Johnson et al., 1992; Rowinsky
et al., 1992; Wall et al., 1992; Blaney et al., 1993; Hochster et
al., 1994; Verweij et al., 1993; Creemers et al., 1994 for
review). The results of preclinical and clinical studies indicate
enhanced antineoplastic activity of topotecan when adminis-
tered daily for prolonged periods of time (Giovanella et al.,
1989; Burris et al., 1992; Houghton et al., 1992; Rowinsky et
al., 1992; Hochster et al., 1994; Verweij et al., 1993). Also,
preclinical studies with oral topotecan have shown that it has
efficacy against rhabdomyosarcoma and colon carcinoma in
mice (Houghton et al., 1992). The unique mechanism of
action and lack of cross-resistance evidence with many well-
known currently available anti-tumour agents may provide
therapeutic advantage in first-line or second-line chemother-
apy. Furthermore, combination therapy of topotecan and
other available antineoplastic agents may well be advanta-
geous (Miller et al., 1993; Rothenberg et al., 1993). In view of
the data suggesting the importance of prolonged exposure to
topotecan for better anti-tumour activity and the impracti-
cality of achieving this exposure by intravenous administra-
tion, an oral formulation is being developed.
In the present study the bioavailability and pharmacoki-
netics of oral topotecan are explored in patients with solid
tumours with the aim of providing a basis for further
development of clinical studies using chronic oral topotecan.
Patient selection, materials and methods
Patient selection and treatment schedule
All patients gave written informed consent according to local
regulatory requirements. Eligibility for the clinical study
required a pathologically confirmed small-cell lung cancer,
colon cancer or ovarian cancer refractory to standard therapy
or for which cancer type no therapy of proven benefit exists.
The performance status had to be <2 on the WHO scale and
life expectancy >3 months. The minimum age was 18 and
maximum age 75 years. The haemoglobulin had to be
>6.0 mmol 1-1 (9 g dl-'), WBC. 3500 ul-', granulocytes
, 1000 l-d and platelets >100 000 jil-'. The serum
creatinine had to be < 140 imol 1-1 (1.6 mg dl-'), the serum
bilirubin <26 ,umol 1` (1.5 mg dl-') and alkaline phospha-
tase and transaminases <2 times the upper normal limit if
liver metastases were absent or -5 times the upper normal
limit if liver metastases were present.
Topotecan was administered orally and intravenously at a
dose of 1.5 mg m-2. Topotecan as supplied for intravenous
infusion was diluted for oral dosage. Each 5 mg vial of
topotecan was reconstituted with 10 ml of 5% dextrose
injection solution to give a 0.5 mg ml-' solution of the drug.
The dose was placed in a beaker containing 100 ml of 5%
dextrose injection solution. On day 1, patients were asked to
drink the entire contents. Subsequently, an additional 100 ml
of 5% dextrose injection solution was added to the beaker
and taken by the patient. On day 2 topotecan was
administered at the same dose as a continuous 30 min
intravenous infusion. The 5 mg vials of topotecan were
reconstituted in 5% dextrose and the appropriate volume was
then added to a volume of 50 ml of 5% dextrose. The drug
was given at approximately the same time of day, between
08.00 and 11.00 h. On both days of drug administration the
patients were fasted for 4 h before the time schedule for
dosing. Fasting continued for a further 2 h after drug
administration on both days. Fluid intake was not restricted.
Blood sample collection
Serial heparinised blood samples (2.8 ml) were collected on
both days of drug administration through an indwelling
intravenous cannula that was inserted in the arm contra-
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lateral to that which was used for the infusion. Blood samples
were taken at 0, 10, 20, 30 and 45 min and 1, 1.5, 2.5, 3.5, 4.5,
6.5 and 8.5 h after start of drug administration. After
collection, the blood samples were centrifuged immediately
for 5 min at 3500 r.p.m. One millilitre of the plasma was
immediately transferred to a polypropylene tube containing
4 ml ofcold methanol (-20°C) and mixed on a whirl mixer for
15 s. Subsequently, the mixture was centrifuged for 5 min at
3500 r.p.m. and theclear supernatant was transferred to a clean
polypropylene tube, closed tightly and stored immediately at
-80°C until analysis. Analysis took place within 1 month.
Chemicals
All chemicals were obtained from Baker (Deventer, The
Netherlands) and were of analytical grade or higher.
Instruments
The high-performance liquid chromatography (HPLC)
apparatus consisted of a pumping device model 6000A
(Waters, Milford, MA, USA), a model SP 8880 automated
sample injection device (Spectra Physics, Santa Clara, CA,
USA), a Perkin Elmer LS40 fluorescence detector (excitation
wavelength 381 nm, emission wavelength 527 nm; Perkin
Elmer, Norwalk, CT, USA) and a model SP-4290 data
analysis system (Spectra Physics). Separation was achieved
with a LiChrosorb RP-18 (particle size 5 ,um) column
(125 x 4 mm i.d.; Merck, Darmstadt, Germany).
Assay of topotecan and hydroxy acid
Topotecan and the hydroxy acid were analysed simulta-
neously with an automated reversed-phase HPLC system and
fluorescence detection as described by Beijnen et al. (1990),
with modifications to reduce the lower limit of quantitation
(LLQ) (Loos et al., 1996). The LLQ was 0.1 ng ml 'for
topotecan as well as for the hydroxy acid. Data were
accepted if the deviation from the nominal value of the
individual calibration samples and quality controls was
<15% (20% at the LLQ).
Pharmacokinetic analysis
The areas under the plasma concentration-time curves
(AUC) of topotecan and hydroxy acid were calculated with
compartmental and non-compartmental analysis using the
Siphar software package release 4.0 (Siphar SIMED, Creteil,
France). The trapezoidal method was used for the non-
compartmental analysis. The AUC(t) was calculated up to
the latest measured time point. The total AUC (AUCoo) was
calculated after extrapolation of the curve to infinity where
appropriate using the terminal elimination rate constant k.
The apparent bioavailability was calculated as the ratio ofthe
AUC(t) after oral and i.v. administration. All concentration-
time profiles were fitted using the extended least squares
method (LSM) (Sheiner and Beal, 1985). The volume of
distribution at steady state (Vd,ss) and total plasma clearance
(Cl=dose/AUC) were calculated after i.v. administration of
topotecan using the AUC extrapolated to infinity (AUCoo).
The terminal half-life (tl/2) was calculated after oral and i.v.
administration as ln2/k.
Visual inspection of the concentration-time curves, the
objective function and the Akaike information criterion
(Yamaoka et al., 1978) were applied to choose the optimal
model for quantitation of the AUC.
Statistical analysis
The Pearson correlation coefficient was calculated between
the ratio of the AUC(t) of the hydroxy acid and topotecan
after oral and i.v. administration and between the ratio of the
AUC(t) of the hydroxy acid after oral and i.v. administration
and the bioavailability. Two-sided paired and unpaired t-tests
were applied to determine any significant difference between
the half-lives of topotecan and hydroxy acid after oral and
i.v. administration. The influence of the presence of liver
metastases and concomitant medication on bioavailability
and clearance were evaluated with the Mann-Whitney U-
test. The relationship between age and bioavailability and
clearance was evaluated with the Pearson correlation
coefficient and the Wilcoxon rank sum test.
Results
Patients and treatment
Twelve patients were included in the study (seven males and
five females). The mean age was 62+7.5 years (range 46-70).
The median performance score was 1 (range 0 -2). Nine
patients had metastatic colon cancer, two had small-cell lung
cancer and one ovarian cancer. Nine patients had
documented liver metastases. Five patients did not use
concomitant medication, two used a benzodiazepine, one
used slow-release morphine and diclofenac, one disopyra-
mide, one alizapride and diclofenac, one atenolol and one
atenolol, furosemide, nifedipine, naproxen, budesonide by
inhalation, acetylsalicylic acid and nitroglycerine. All patients
had been entered in phase II studies applying topotecan in a
daily x 5 schedule with cycles repeated every 3 weeks. Oral
administration of topotecan was without exception on the
first day of one of the 5 day treatment cycles. Neither i.v. nor
oral administration was associated with any significant acute
side-effect. The oral drinking solution was well tolerated.
Pharmacokinetic analysis
Representative plasma concentration-time curves of topote-
can and hydroxy acid after oral and i.v. administration are
given in Figure 1. Concentrations of topotecan lactone and
hydroxy acid were always undetectable on day 2, before
administration ofthe second dose. In only 6 out of 12 patients
visual inspection of the obtained concentration-time profiles
oftopotecan after oral administration revealed a good fit ofthe
measured plasma concentration-time points, applying ex-
tended LSM and one-, two- or three-compartment models [the
corresponding correlation coefficients (r) were >0.97]. All i.v.
profiles of topotecan could be fitted well (r>0.97) applying
LSM and the outlined models. In ten patients the model using a
two-exponential decline of the concentration -time curve
resulted in the highest correlation coefficient and lowest
Akaike value. In one patient the model with a three-
exponential decline of the curve and in one other patient a
one-exponential decline resulted in the best fit. In most patients
thecurves ofthehydroxy acidcould not befittedproperlyusing
extended LSM, assuming linear pharmacokinetics. The plasma
concentration-time curves of the hydroxy acid were higher
than those of topotecan in all patients. The pharmacokinetic
data are summarised in Tables I and II.
After oral administration the per cent of the AUC
extrapolated in eight patients was >20%, therefore the
bioavailability was calculated using the ratio ofAUC(t) instead
ofthe AUC extrapolated to infinity (AUCoo). The mean+s.d.
of the AUC(t) of topotecan after oral administration was
15.18+5.51 ng h-' ml-' (range 9.38-25.37 ng h-' ml-'; Ta-
ble I). The AUC(t) of topotecan after i.v. administration was
49.87+ 10.87 ng h-'ml-' (range 32.50-73.68 ng h-'ml-').
The AUCoo of topotecan after i..v. administration was
61.02+ 10.57 ng h ' ml- (range 43.70 -81.08 ng h ' ml-').
The bioavailability was 30% +7.7% (range 21% -45%). The
coefficient ofvariation (CV) was 25.4%. Ifthe curves had been
extrapolatedtoinfinity, thenthebioavailabilitywouldhavebeen
calculated as 32% + 11.5%.
The median of the Tmax was 0.78 h and the range 0.33-
2.5 h. The half-life for the initial decline of the plasma
concentration-time curve (t1/2 .) after i.v. administration was
0.186+0.054 h based on the data for the ten patients that
were fitted with a biexponential model.Table II Mean pharmacokinetic data of topotecan lactone
Oral Intravenous
Cl (ml min-1) - 824+ 117 (n= 12)
(535-1068)
Vd,SS (1) - 128+ 37.1 (n = 12)
(86-231)
t/2p (h) 2.43± 1.15 (n= 10) 2.40+0.38 (n= 12)
(1.02-3.20) (1.72-2.93)
Meani s.d. and range are given. Cl, total plasma clearance. Vd,ssg
volume ofdistribution at steady state.
1992; Houghton et al., 1992; Rowinsky et al., 1992; Hochster
-4 B1 I ACA. -4or ) 1 I^z (VII 'ru _r
0 2 4
Time (h)
Figure 1 Plasma concentration -time c
hydroxy acid in a patient after oral an
3.2mg of topotecan. A, i.v. topotecan; 4
oral topotecan; 0, oral hydroxy acid;
topotecan and the dotted lines the hydrc
The ratio of the AUC(t) of topot
acid after oral administration was 0.63
i.v. administration 0.72+0.16. The coI
0.87 (P=0.002). The ratio of the AUC
after oral and i.v. administration v
which is of the same magnitude as
topotecan. The correlation coefficient
the bioavailability was 0.84 (P=0.004
There was no significant relatior
gender and bioavailability. In ad
significant relationship between th
metastases and the magnitude of the I
The Cmax of the hydroxy acid after (
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was 2.82 +0.85 h and after i.v. admi
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Discussion
The present study is the first to provid
exposure of topotecan after oral as
administration of topotecan result
antineoplastic activity (Giovanella et i
6 8 10 et al., 1994; verweuj et al., 199J). Ite concept oI cnronic administration is to some extent applied in a large number of
phase II studies that are currently in progress using a daily
-urve of topotecan and x 5 intravenous infusion of 30 min or 21 day continuous
d iv. administration of infusion. Topotecan may show an even more pronounced
I, i.v. hydroxy acid; anti-tumour response if the exposure duration is even further
closed lines represent prolonged (Hochster et al., 1994). It would increase the
xy acid. convenience for the patient substantially if the drug on a
chronic treatment schedule could be taken orally.
The apparent bioavailability was determined in 12 patients
tecan and the hydroxy with various types of solid tumours. The bioavailability
+0.25 (n =9) and after ranged from 21% to 45%. The term apparent bioavailability
rrelation coefficient was has been used because topotecan undergoes a reversible, pH-
>(t) of the hydroxy acid dependent conversion to the hydroxy acid at physiological
vas 0.38 +0.12 (n = 9), pH and the standard equation for the calculation of
the bioavailability of bioavailability no longer applies. The correct equations
between this ratio and contain terms for the AUC of topotecan, and hydroxy acid
after i.v. administration of the hydroxy acid itself. The
iship between age or standard equation for bioavailability, as used in this study, is
lition, there was no a function not only of dose and input rate, but also of
le presence of liver conversion clearance. The accuracy of the apparent bioavail-
bioavailability. ability data will depend, to a large extent, on the magnitude
oral administration was of the conversion clearance, for which no in vivo data on
ng ml-1) and after i.v. topotecan are available. Even although at physiological pH
(range 15.35- the formation of the hydroxy acid is the predominant
er oral administration reaction, experiments on camptothecin in the rat have
nistration 3.22+0.73 h shown that the lactone can be formed following the i.v.
administration of the hydroxy acid (Scott et al., 1994). As
camptothecin and topotecan have the same basic ring
structure, it is highly likely that topotecan could also be
formed following administration of the topotecan hydroxy
acid. The bioavailability was determined after oral adminis-
le data on the systemic tration on day 1 and i.v. administration on day 2. This
dministration. Chronic strategy was followed to deviate as little as possible from the
Led in an enhanced phase II daily x 5 schedule that has documented therapeutic
al., 1989; Burris et al., activity in several tumour types. The approach is justified
Table I Individual pharmacokinetic data of topotecan lactone and hydroxy acid
Topotecan Hydroxy acid
Patient Dose Tmax, 0 Cmax, 0 Cmax, i.v. AUC(t), 0 AUC(t), i.v. AUCoo i.v. F AUC(t), 0 AUC(t), i.v.
(no.) (mg) (h) (ng mr') (ng mr') (ng h- ml-) (ng h-1 mr') (ng h-' mr') (%) (ng h-1 ml-) (ng h-1 ml-)
1 2.7 0.5 5.95 41.08 10.48 49.17 64.49 21 NE 59.86
2 2.8 1.03 5.93 35.92 9.38 32.50 43.70 30 12.20 37.08
3 3.2 0.33 5.16 43.86 10.85 42.37 56.34 25 15.10 60.72
4 3.0 1.13 5.45 41.81 18.81 49.37 58.15 38 47.96 90.79
5 2.7 0.52 5.71 33.40 11.25 37.96 46.64 30 NE 56.34
6 3.0 0.55 7.14 47.18 12.75 55.09 69.62 23 29.30 100.83
7 2.8 1.03 4.71 40.35 9.79 45.31 59.53 22 NE 65.07
8 2.8 2.5 5.08 41.41 21.98 48.57 52.04 45 63.99 103.25
9 3.1 0.5 6.48 41.21 12.46 55.00 66.00 23 19.22 57.70
10 2.6 1.5 6.67 42.11 25.37 73.68 81.08 34 51.47 121.14
11 2.8 1.0 5.38 25.35 21.56 62.31 70.14 35 19.01 63.77
12 2.7 0.5 6.93 19.57 17.00 46.61 64.55 36 24.46 62.48
Mean 5.88 37.77 15.18 49.87 61.02 30 31.41 73.25
s.d. 0.78 8.04 5.51 10.87 10.57 7.7 18.47 24.69
0, oral; i.v., intravenous; dose, absolute dose (oral = i.v.); Tmax, time to maximal plasma concentration; Cmax, maximal plasma concentration;
AUC(t), area under the curve up to the latest measured time point; AUCoo, area under the curve extrapolated to infinity; NE, not evaluated.
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because there is no carryover of topotecan into the second
treatment period. In addition, topotecan is not metabolised
and therefore cannot induce its own elimination. Plasma
samples were collected up to 8 h after oral administration.
This was slightly too short to extrapolate the AUC up to
infinity. The sampling time was determined based on
preclinical data on the oral administration in dogs and on
the elimination pharmacokinetics after i.v. administration in
man. The bioavailability after oral administration in dogs
was 35.7% + 16.3% (unpublished data), which is close to the
result obtained in patients. The calculation of the bioavail-
ability using the AUCoo resulted in only a marginally higher
value of 32% instead of 30%. Apparently, the applied ratio
of AUC(t) gives a good estimate of the bioavailability.
The t1/2 fl in the patient with the highest bioavailability of
45% was 1.8 h after i.v. and 3.2 h after oral administration.
This difference was relatively large in comparison with the
data obtained in the other patients. This patient had a large
tumour in the upper part of the abdomen. It cannot be
excluded that this extensive tumour mass has influenced the
rate ofpassage of topotecan through the gastrointestinal tract
and thereby the magnitude ofthe absorption. The Tmax ofthis
patient was 2.5 h, which is delayed compared with the range
of the other 11 patients (0.33- 1.5 h).
The CV of the AUC(t) after oral administration was
36.6% and after i.v. administration 21.8%. Hence, oral
administration increased the interpatient difference in
systemic exposure markedly. It has to be elucidated in
follow-up studies whether this variation has clinical implica-
tions. In addition, the intra-patient variability needs to be
determined in future studies.
The CV of the plasma clearance of topotecan after i.v.
administration was 18.8%. The range of the data was of the
same order as reported by Rowinsky et al. (1992) and Verweij
et al. (1993).
No relationships were found between patient character-
istics such as age, gender, performance score and the
bioavailability. In addition, the presence of liver metastases
or concomitant drugs did not seem to be related to the
magnitude of the bioavailability.
The ratio of topotecan and hydroxy acid was of the
same order after oral and i.v. administration. There would
appear only two reasonable explanations for the observed
data: either topotecan is poorly absorbed from the
gastrointestinal tract or topotecan is well absorbed but a
large part of the dose is converted presystemically in the
gut into the hydroxy acid, which is itself not absorbed to
any appreciable extent. The good water solubility of
topotecan coupled with the rapid absorption would suggest
that the second explanation can best describe the data
obtained in this study. There is no evidence for the
formation of other metabolites that may explain the
observed data.
The bioavailability of topotecan after oral administration
illustrates significant systemic exposure to the drug which
may enable chronic oral treatment.
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